Cargando…
Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for the development of improved diagnostics, therapeutics, and vaccines. Here, we report the longitudinal analysis of three COVID...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067489/ https://www.ncbi.nlm.nih.gov/pubmed/33917609 http://dx.doi.org/10.3390/pathogens10040438 |
_version_ | 1783682815574933504 |
---|---|
author | Heidepriem, Jasmin Dahlke, Christine Kobbe, Robin Santer, René Koch, Till Fathi, Anahita Seco, Bruna M. S. Ly, My L. Schmiedel, Stefan Schwinge, Dorothee Serna, Sonia Sellrie, Katrin Reichardt, Niels-Christian Seeberger, Peter H. Addo, Marylyn M. Loeffler, Felix F. |
author_facet | Heidepriem, Jasmin Dahlke, Christine Kobbe, Robin Santer, René Koch, Till Fathi, Anahita Seco, Bruna M. S. Ly, My L. Schmiedel, Stefan Schwinge, Dorothee Serna, Sonia Sellrie, Katrin Reichardt, Niels-Christian Seeberger, Peter H. Addo, Marylyn M. Loeffler, Felix F. |
author_sort | Heidepriem, Jasmin |
collection | PubMed |
description | The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for the development of improved diagnostics, therapeutics, and vaccines. Here, we report the longitudinal analysis of three COVID-19 patients with moderate (#1) and mild disease (#2 and #3). Antibody serum responses were analyzed using spike glycoprotein enzyme linked immunosorbent assay (ELISA), full-proteome peptide, and glycan microarrays. ELISA immunoglobulin A, G, and M (IgA, IgG, and IgM) signals increased over time for individuals #1 and #2, whereas #3 only showed no clear positive IgG and IgM result. In contrast, peptide microarrays showed increasing IgA/G signal intensity and epitope spread only in the moderate patient #1 over time, whereas early but transient IgA and stable IgG responses were observed in the two mild cases #2 and #3. Glycan arrays showed an interaction of antibodies to fragments of high-mannose and core N-glycans, present on the viral shield. In contrast to protein ELISA, microarrays allow for a deeper understanding of IgA, IgG, and IgM antibody responses to specific epitopes of the whole proteome and glycans of SARS-CoV-2 in parallel. In the future, this may help to better understand and to monitor vaccination programs and monoclonal antibodies as therapeutics. |
format | Online Article Text |
id | pubmed-8067489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80674892021-04-25 Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series Heidepriem, Jasmin Dahlke, Christine Kobbe, Robin Santer, René Koch, Till Fathi, Anahita Seco, Bruna M. S. Ly, My L. Schmiedel, Stefan Schwinge, Dorothee Serna, Sonia Sellrie, Katrin Reichardt, Niels-Christian Seeberger, Peter H. Addo, Marylyn M. Loeffler, Felix F. Pathogens Article The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for the development of improved diagnostics, therapeutics, and vaccines. Here, we report the longitudinal analysis of three COVID-19 patients with moderate (#1) and mild disease (#2 and #3). Antibody serum responses were analyzed using spike glycoprotein enzyme linked immunosorbent assay (ELISA), full-proteome peptide, and glycan microarrays. ELISA immunoglobulin A, G, and M (IgA, IgG, and IgM) signals increased over time for individuals #1 and #2, whereas #3 only showed no clear positive IgG and IgM result. In contrast, peptide microarrays showed increasing IgA/G signal intensity and epitope spread only in the moderate patient #1 over time, whereas early but transient IgA and stable IgG responses were observed in the two mild cases #2 and #3. Glycan arrays showed an interaction of antibodies to fragments of high-mannose and core N-glycans, present on the viral shield. In contrast to protein ELISA, microarrays allow for a deeper understanding of IgA, IgG, and IgM antibody responses to specific epitopes of the whole proteome and glycans of SARS-CoV-2 in parallel. In the future, this may help to better understand and to monitor vaccination programs and monoclonal antibodies as therapeutics. MDPI 2021-04-06 /pmc/articles/PMC8067489/ /pubmed/33917609 http://dx.doi.org/10.3390/pathogens10040438 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Heidepriem, Jasmin Dahlke, Christine Kobbe, Robin Santer, René Koch, Till Fathi, Anahita Seco, Bruna M. S. Ly, My L. Schmiedel, Stefan Schwinge, Dorothee Serna, Sonia Sellrie, Katrin Reichardt, Niels-Christian Seeberger, Peter H. Addo, Marylyn M. Loeffler, Felix F. Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title | Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title_full | Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title_fullStr | Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title_full_unstemmed | Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title_short | Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series |
title_sort | longitudinal development of antibody responses in covid-19 patients of different severity with elisa, peptide, and glycan arrays: an immunological case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067489/ https://www.ncbi.nlm.nih.gov/pubmed/33917609 http://dx.doi.org/10.3390/pathogens10040438 |
work_keys_str_mv | AT heidepriemjasmin longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT dahlkechristine longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT kobberobin longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT santerrene longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT kochtill longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT fathianahita longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT secobrunams longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT lymyl longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT schmiedelstefan longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT schwingedorothee longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT sernasonia longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT sellriekatrin longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT reichardtnielschristian longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT seebergerpeterh longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT addomarylynm longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT loefflerfelixf longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries AT longitudinaldevelopmentofantibodyresponsesincovid19patientsofdifferentseveritywithelisapeptideandglycanarraysanimmunologicalcaseseries |